Jakafi 10 mg Oral Tablet
RxNorm 1193337

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1193337 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Jakafi 10 mg Oral Tablet.

The following semantic concepts and normalized strings are associated with this clinical entity:

SY
Jakafi (as ruxolitinib phosphate) 10 mg Oral Tablet
AUI:3871933
PSN
Jakafi 10 mg Oral Tablet
AUI:6368059
SY
Jakafi 10 mg Oral Tablet
AUI:3871932
SBD
Ruxolitinib 10 mg Oral Tablet [Jakafi]
AUI:3871931

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SYPrescribable

Synonym (SY):
Jakafi (as ruxolitinib phosphate) 10 mg Oral Tablet
(Atom ID: 3871933)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Jakafi (as ruxolitinib phosphate) 10 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1193337
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
3871933
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1193337
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

PSNPrescribable

Prescribable Name (PSN):
Jakafi 10 mg Oral Tablet
(Atom ID: 6368059)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Jakafi 10 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1193337
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6368059
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1193337
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

SYPrescribable

Synonym (SY):
Jakafi 10 mg Oral Tablet
(Atom ID: 3871932)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Jakafi 10 MG Oral Tablet
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1193337
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
3871932
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1193337
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

SBDPrescribable

Semantic Branded Drug (SBD):
Ruxolitinib 10 mg Oral Tablet [Jakafi]
(Atom ID: 3871931)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
ruxolitinib 10 MG Oral Tablet [Jakafi]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1193337
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
3871931
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
1193337
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{1193327} 1193325
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{1193327} 1193326
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
10 MG
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{1193327} AM
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXTERM FORM
Tab
The RxTerm dose form name for this drug

Patient Education

Ruxolitinib


Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). It is also used to treat polycythemia vera (PV; a slow growing cancer of the blood in which the bone marrow makes too many red blood cells) in people who were not able to be treated successfully with hydroxyurea. Ruxolitinib is also used to treat graft versus host disease (GVHD; a complication of hematopoietic stem-cell transplant [HSCT; a procedure that replaces diseased bone marrow with healthy bone marrow]) in adults and children 12 years of age and older who were treated unsuccessfully with steroid medications. Ruxolitinib is in a class of medications called kinase inhibitors. It works to treat myelofibrosis and PV by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. It works to treat GVHD by blocking the signals of the cells that cause GVHD.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.